{
 "disease": "myeloproliferative-neoplasms",
 "label": "Myeloproliferative neoplasms",
 "url": "https://usebiotransfer.org/disease/myeloproliferative-neoplasms/",
 "built": "2026-09-17",
 "facts_hash": {
  "answers": "f753ca7602e6",
  "targets": "930961e3f672"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-17",
  "trials": "2026-09-17"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "JAK2",
   "ensembl": "ENSG00000096968",
   "n_drug_entries": 31,
   "n_distinct_drugs": 26,
   "drugs": {
    "AC-430": "PHASE_1",
    "AT-9283": "PHASE_3",
    "AZD-1480": "PHASE_2",
    "BARICITINIB": "APPROVAL",
    "BMS-911543": "PHASE_2",
    "CT-1578": "PHASE_1",
    "DELGOCITINIB": "APPROVAL",
    "DEURUXOLITINIB": "APPROVAL",
    "FEDRATINIB": "APPROVAL",
    "FILGOTINIB": "APPROVAL",
    "GANDOTINIB": "PHASE_2",
    "GUSACITINIB": "PHASE_2",
    "IZENCITINIB": "PHASE_2_3",
    "LESTAURTINIB": "APPROVAL",
    "MOMELOTINIB": "APPROVAL",
    "MOMELOTINIB DIHYDROCHLORIDE": "APPROVAL",
    "NEZULCITINIB": "PHASE_2",
    "NS-018": "PHASE_2",
    "PACRITINIB": "APPROVAL",
    "PEFICITINIB": "PHASE_3",
    "RUXOLITINIB": "APPROVAL",
    "TOFACITINIB": "APPROVAL",
    "UPADACITINIB": "APPROVAL",
    "UPADACITINIB HEMIHYDRATE": "APPROVAL",
    "XL-019": "PHASE_3",
    "ZOTIRACICLIB": "PHASE_1_2"
   },
   "approved": [
    "BARICITINIB",
    "DELGOCITINIB",
    "DEURUXOLITINIB",
    "FEDRATINIB",
    "FILGOTINIB",
    "LESTAURTINIB",
    "MOMELOTINIB",
    "MOMELOTINIB DIHYDROCHLORIDE",
    "PACRITINIB",
    "RUXOLITINIB",
    "TOFACITINIB",
    "UPADACITINIB",
    "UPADACITINIB HEMIHYDRATE"
   ],
   "n_approved": 13,
   "approved_for": {
    "BARICITINIB": [
     "juvenile idiopathic arthritis",
     "atopic eczema",
     "rheumatoid arthritis",
     "juvenile dermatomyositis"
    ],
    "DELGOCITINIB": [
     "atopic eczema",
     "Eczematoid dermatitis",
     "dermatitis"
    ],
    "DEURUXOLITINIB": [
     "alopecia areata"
    ],
    "FEDRATINIB": [
     "myeloproliferative disorder",
     "primary myelofibrosis",
     "myelofibrosis",
     "acquired polycythemia vera"
    ],
    "FILGOTINIB": [
     "rheumatoid arthritis"
    ],
    "LESTAURTINIB": [
     "acute myeloid leukemia by FAB classification"
    ],
    "MOMELOTINIB": [
     "myelofibrosis"
    ],
    "MOMELOTINIB DIHYDROCHLORIDE": [
     "myelofibrosis",
     "Splenomegaly",
     "myeloproliferative disorder"
    ],
    "PACRITINIB": [
     "myelofibrosis",
     "primary myelofibrosis",
     "acquired polycythemia vera"
    ],
    "RUXOLITINIB": [
     "essential thrombocythemia",
     "myelofibrosis",
     "Eczematoid dermatitis",
     "myeloproliferative disorder",
     "graft versus host disease",
     "acquired polycythemia vera",
     "chronic graft versus host disease",
     "vitiligo",
     "primary myelofibrosis"
    ],
    "TOFACITINIB": [
     "psoriatic arthritis",
     "rheumatoid arthritis"
    ],
    "UPADACITINIB": [
     "rheumatoid arthritis",
     "atopic eczema",
     "ulcerative colitis",
     "Crohn disease",
     "psoriatic arthritis",
     "temporal arteritis",
     "ankylosing spondylitis"
    ],
    "UPADACITINIB HEMIHYDRATE": [
     "rheumatoid arthritis",
     "ulcerative colitis"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CALR",
   "ensembl": "ENSG00000179218",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "MPL",
   "ensembl": "ENSG00000117400",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "AVATROMBOPAG": "APPROVAL",
    "ELTROMBOPAG": "APPROVAL",
    "ELTROMBOPAG CHOLINE": "APPROVAL",
    "ELTROMBOPAG OLAMINE": "APPROVAL",
    "HETROMBOPAG OLAMINE": "PHASE_3",
    "LUSUTROMBOPAG": "APPROVAL",
    "RAFUTROMBOPAG": "PHASE_3",
    "ROMIPLOSTIM": "APPROVAL"
   },
   "approved": [
    "AVATROMBOPAG",
    "ELTROMBOPAG",
    "ELTROMBOPAG CHOLINE",
    "ELTROMBOPAG OLAMINE",
    "LUSUTROMBOPAG",
    "ROMIPLOSTIM"
   ],
   "n_approved": 6,
   "approved_for": {
    "AVATROMBOPAG": [
     "hemorrhage",
     "Thrombocytopenia",
     "liver disorder"
    ],
    "ELTROMBOPAG": [
     "hemorrhage",
     "Thrombocytopenia",
     "autoimmune thrombocytopenic purpura"
    ],
    "ELTROMBOPAG CHOLINE": [
     "chronic hepatitis C virus infection",
     "aplastic anemia",
     "autoimmune thrombocytopenic purpura"
    ],
    "ELTROMBOPAG OLAMINE": [
     "severe aplastic anemia",
     "autoimmune thrombocytopenic purpura",
     "Thrombocytopenia",
     "chronic hepatitis C virus infection",
     "thrombocytopenic purpura"
    ],
    "LUSUTROMBOPAG": [
     "hemorrhage",
     "Thrombocytopenia"
    ],
    "ROMIPLOSTIM": [
     "thrombocytopenic purpura",
     "hemorrhage",
     "Thrombocytopenia",
     "autoimmune thrombocytopenic purpura"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "TET2",
   "ensembl": "ENSG00000168769",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "ASXL1",
   "ensembl": "ENSG00000171456",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "EZH2",
   "ensembl": "ENSG00000106462",
   "n_drug_entries": 3,
   "n_distinct_drugs": 3,
   "drugs": {
    "GSK2816126": "PHASE_1",
    "TAZEMETOSTAT": "APPROVAL",
    "TAZEMETOSTAT HYDROBROMIDE": "APPROVAL"
   },
   "approved": [
    "TAZEMETOSTAT",
    "TAZEMETOSTAT HYDROBROMIDE"
   ],
   "n_approved": 2,
   "approved_for": {
    "TAZEMETOSTAT": [
     "follicular lymphoma"
    ],
    "TAZEMETOSTAT HYDROBROMIDE": [
     "follicular lymphoma",
     "sarcoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "SRSF2",
   "ensembl": "ENSG00000161547",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "U2AF1",
   "ensembl": "ENSG00000160201",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "IDH2",
   "ensembl": "ENSG00000182054",
   "n_drug_entries": 4,
   "n_distinct_drugs": 2,
   "drugs": {
    "ENASIDENIB": "APPROVAL",
    "VORASIDENIB": "APPROVAL"
   },
   "approved": [
    "ENASIDENIB",
    "VORASIDENIB"
   ],
   "n_approved": 2,
   "approved_for": {
    "ENASIDENIB": [
     "acute myeloid leukemia by FAB classification",
     "acute myeloid leukemia"
    ],
    "VORASIDENIB": [
     "astrocytoma (excluding glioblastoma)",
     "oligodendroglioma",
     "glioma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "SH2B3",
   "ensembl": "ENSG00000111252",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "NFE2",
   "ensembl": "ENSG00000123405",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "JAK": {
    "n": 231,
    "n_observational": 36,
    "n_active": 88,
    "n_withdrawn": 11,
    "trials": [
     {
      "nct": "NCT04116502",
      "title": "MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04176198",
      "title": "A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04282187",
      "title": "Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04370301",
      "title": "Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644211",
      "title": "Ruxolitinib in Thrombocythemia and Polycythemia Vera",
      "status": "RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05037760",
      "title": "A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05280509",
      "title": "Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Na\u00efve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib",
      "status": "RECRUITING",
      "last_update": "2023-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05423691",
      "title": "Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs",
      "status": "RECRUITING",
      "last_update": "2025-04-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05488548",
      "title": "Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-01-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05817955",
      "title": "Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN",
      "status": "RECRUITING",
      "last_update": "2023-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05870475",
      "title": "Pegylated Interferon \u03b1-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV",
      "status": "RECRUITING",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05980806",
      "title": "A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-na\u00efve Myelofibrosis and Moderate Thrombocytopenia",
      "status": "RECRUITING",
      "last_update": "2026-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06034002",
      "title": "A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06122831",
      "title": "A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)",
      "status": "RECRUITING",
      "last_update": "2025-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06150157",
      "title": "A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06159491",
      "title": "Pacritinib in CMML",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06218628",
      "title": "Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition",
      "status": "RECRUITING",
      "last_update": "2024-05-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06291987",
      "title": "Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06303193",
      "title": "Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06327100",
      "title": "Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)",
      "status": "RECRUITING",
      "last_update": "2026-05-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06343805",
      "title": "A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06345495",
      "title": "High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06414681",
      "title": "Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined",
      "status": "RECRUITING",
      "last_update": "2026-05-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06477549",
      "title": "BeFluBu vs FluBuRux Conditioning in Haploidentical HCT",
      "status": "RECRUITING",
      "last_update": "2024-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06479135",
      "title": "Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Na\u00efve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib",
      "status": "RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06517875",
      "title": "Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06605586",
      "title": "Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition",
      "status": "RECRUITING",
      "last_update": "2025-03-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06770842",
      "title": "Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2025-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06773195",
      "title": "A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859424",
      "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06887803",
      "title": "A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors",
      "status": "RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07033598",
      "title": "Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07071155",
      "title": "Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-03-27",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07104799",
      "title": "Momelotinib During and After HCT in Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07128381",
      "title": "Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07148947",
      "title": "Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07228624",
      "title": "Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07238712",
      "title": "Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor",
      "status": "RECRUITING",
      "last_update": "2025-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07249346",
      "title": "Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07249840",
      "title": "Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07357727",
      "title": "A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07394153",
      "title": "Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07551427",
      "title": "A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623161",
      "title": "A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00463385",
      "title": "A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia",
      "status": "COMPLETED",
      "last_update": "2019-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00494585",
      "title": "CEP-701 for PH-negative Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2012-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00509899",
      "title": "Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2018-03-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00586651",
      "title": "Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis",
      "status": "COMPLETED",
      "last_update": "2015-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00606307",
      "title": "Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases",
      "status": "COMPLETED",
      "last_update": "2019-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00631462",
      "title": "A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2009-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00667277",
      "title": "Phase II Study of Bevacizumab (Avastin\u00ae) in Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2014-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00668421",
      "title": "CEP-701 (Lestaurtinib) in Myelofibrosis",
      "status": "UNKNOWN",
      "last_update": "2014-11-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00674479",
      "title": "INCB018424 in Patients With Advanced Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00719836",
      "title": "A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies",
      "status": "COMPLETED",
      "last_update": "2012-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00724334",
      "title": "A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2025-03-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00726232",
      "title": "Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia",
      "status": "TERMINATED",
      "last_update": "2025-10-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00745550",
      "title": "A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2012-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00910728",
      "title": "Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases",
      "status": "COMPLETED",
      "last_update": "2017-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00934544",
      "title": "Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial",
      "status": "COMPLETED",
      "last_update": "2019-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00935987",
      "title": "Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)",
      "status": "COMPLETED",
      "last_update": "2019-02-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00952289",
      "title": "COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial",
      "status": "COMPLETED",
      "last_update": "2018-03-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01038856",
      "title": "Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera",
      "status": "TERMINATED",
      "last_update": "2020-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01134120",
      "title": "A Study in Myeloproliferative Disorders",
      "status": "COMPLETED",
      "last_update": "2018-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01164163",
      "title": "INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",
      "status": "COMPLETED",
      "last_update": "2014-10-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01236638",
      "title": "Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)",
      "status": "COMPLETED",
      "last_update": "2019-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01243944",
      "title": "Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)",
      "status": "COMPLETED",
      "last_update": "2019-03-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01317875",
      "title": "Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)",
      "status": "COMPLETED",
      "last_update": "2025-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01340651",
      "title": "Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients",
      "status": "COMPLETED",
      "last_update": "2014-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01348490",
      "title": "Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)",
      "status": "COMPLETED",
      "last_update": "2020-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01369498",
      "title": "Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2020-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01375140",
      "title": "Ruxolitinib and Lenalidomide for Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01392443",
      "title": "Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF",
      "status": "COMPLETED",
      "last_update": "2019-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01423058",
      "title": "Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2019-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01423851",
      "title": "Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF",
      "status": "COMPLETED",
      "last_update": "2022-03-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01433445",
      "title": "Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2021-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01445769",
      "title": "Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2019-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01493414",
      "title": "INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.",
      "status": "COMPLETED",
      "last_update": "2019-04-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01558739",
      "title": "Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)",
      "status": "COMPLETED",
      "last_update": "2015-03-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01632904",
      "title": "Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study",
      "status": "COMPLETED",
      "last_update": "2017-11-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01644110",
      "title": "Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01692366",
      "title": "Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly",
      "status": "COMPLETED",
      "last_update": "2025-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01693601",
      "title": "Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)",
      "status": "COMPLETED",
      "last_update": "2023-10-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01702064",
      "title": "Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients",
      "status": "COMPLETED",
      "last_update": "2021-01-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01712308",
      "title": "Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia",
      "status": "COMPLETED",
      "last_update": "2023-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01730248",
      "title": "A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2020-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732445",
      "title": "Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2017-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01751425",
      "title": "Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors",
      "status": "TERMINATED",
      "last_update": "2025-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01773187",
      "title": "Pacritinib Versus Best Available Therapy to Treat Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2020-09-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01776723",
      "title": "A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib",
      "status": "COMPLETED",
      "last_update": "2022-09-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01787487",
      "title": "Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm",
      "status": "COMPLETED",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01787552",
      "title": "A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF",
      "status": "COMPLETED",
      "last_update": "2020-04-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01790295",
      "title": "Ruxolitinib Prior to Transplant in Patients With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2019-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01795677",
      "title": "JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2022-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914484",
      "title": "Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01969838",
      "title": "Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2023-05-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01981850",
      "title": "A Phase 2 Study of RO7490677 In Participants With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2022-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01998828",
      "title": "Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia",
      "status": "TERMINATED",
      "last_update": "2020-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02038036",
      "title": "Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.",
      "status": "COMPLETED",
      "last_update": "2021-07-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02055781",
      "title": "Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia",
      "status": "TERMINATED",
      "last_update": "2021-11-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02076191",
      "title": "Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML",
      "status": "COMPLETED",
      "last_update": "2019-02-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02087059",
      "title": "A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2016-07-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02091752",
      "title": "A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)",
      "status": "TERMINATED",
      "last_update": "2016-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02092324",
      "title": "Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02101268",
      "title": "Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF",
      "status": "COMPLETED",
      "last_update": "2023-05-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02124746",
      "title": "Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia",
      "status": "COMPLETED",
      "last_update": "2023-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02158858",
      "title": "A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02226172",
      "title": "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib",
      "status": "TERMINATED",
      "last_update": "2019-01-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02251821",
      "title": "JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02253277",
      "title": "Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients",
      "status": "COMPLETED",
      "last_update": "2019-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257138",
      "title": "Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02267278",
      "title": "Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)",
      "status": "COMPLETED",
      "last_update": "2019-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02292446",
      "title": "Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.",
      "status": "COMPLETED",
      "last_update": "2019-07-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02311569",
      "title": "Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02370706",
      "title": "Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2022-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02386800",
      "title": "CINC424A2X01B Rollover Protocol",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02410551",
      "title": "Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)",
      "status": "TERMINATED",
      "last_update": "2018-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02436135",
      "title": "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease",
      "status": "TERMINATED",
      "last_update": "2020-09-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02469974",
      "title": "Ruxolitinib in Combination With Autotransplant",
      "status": "WITHDRAWN",
      "last_update": "2016-08-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02493530",
      "title": "TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea",
      "status": "COMPLETED",
      "last_update": "2026-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02515630",
      "title": "Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)",
      "status": "COMPLETED",
      "last_update": "2023-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02528877",
      "title": "Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",
      "status": "WITHDRAWN",
      "last_update": "2016-09-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02564536",
      "title": "Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)",
      "status": "WITHDRAWN",
      "last_update": "2017-05-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02577926",
      "title": "The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02584777",
      "title": "A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis",
      "status": "WITHDRAWN",
      "last_update": "2021-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02587598",
      "title": "Study of INCB053914 in Subjects With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2021-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02593760",
      "title": "A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)",
      "status": "COMPLETED",
      "last_update": "2018-05-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02598297",
      "title": "Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.",
      "status": "TERMINATED",
      "last_update": "2019-08-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02711137",
      "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02718300",
      "title": "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2024-05-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02742324",
      "title": "Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg",
      "status": "COMPLETED",
      "last_update": "2022-07-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02765724",
      "title": "Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects",
      "status": "COMPLETED",
      "last_update": "2020-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02784496",
      "title": "Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2025-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02806375",
      "title": "PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2019-04-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02807077",
      "title": "PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects",
      "status": "COMPLETED",
      "last_update": "2018-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02917096",
      "title": "Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2023-12-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02962388",
      "title": "The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line",
      "status": "TERMINATED",
      "last_update": "2021-06-29",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02966353",
      "title": "Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.",
      "status": "COMPLETED",
      "last_update": "2020-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02973711",
      "title": "A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML",
      "status": "WITHDRAWN",
      "last_update": "2021-02-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03069326",
      "title": "A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03123588",
      "title": "Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)",
      "status": "TERMINATED",
      "last_update": "2021-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03144687",
      "title": "A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2022-06-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03165734",
      "title": "A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03194542",
      "title": "A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence",
      "status": "COMPLETED",
      "last_update": "2023-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03222609",
      "title": "A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03287245",
      "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera",
      "status": "TERMINATED",
      "last_update": "2021-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03333187",
      "title": "Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03373877",
      "title": "Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2022-11-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03386214",
      "title": "Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2022-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03427866",
      "title": "Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03441113",
      "title": "Extended Access of Momelotinib in Adults With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03558607",
      "title": "The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm",
      "status": "UNKNOWN",
      "last_update": "2020-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610971",
      "title": "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03627403",
      "title": "Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors",
      "status": "TERMINATED",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03645824",
      "title": "Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2022-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654768",
      "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03669965",
      "title": "KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2020-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03722407",
      "title": "Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03755518",
      "title": "A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib",
      "status": "TERMINATED",
      "last_update": "2024-12-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878199",
      "title": "Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms",
      "status": "TERMINATED",
      "last_update": "2026-04-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03935555",
      "title": "Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib",
      "status": "TERMINATED",
      "last_update": "2022-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03952039",
      "title": "An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib",
      "status": "COMPLETED",
      "last_update": "2025-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04016116",
      "title": "Dual PD-1 and JAK2 Inhibition in Hematological Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2020-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04041050",
      "title": "A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04097821",
      "title": "Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients",
      "status": "TERMINATED",
      "last_update": "2025-08-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04173494",
      "title": "A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)",
      "status": "COMPLETED",
      "last_update": "2023-11-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04217993",
      "title": "Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2023-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04218071",
      "title": "Actuate 1901: 9-ING-41 in Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2024-02-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04243122",
      "title": "Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients",
      "status": "COMPLETED",
      "last_update": "2024-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04279847",
      "title": "Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04281498",
      "title": "Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04285086",
      "title": "Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04328844",
      "title": "A Study to Assess a PI3K\u03b4 Inhibitor (IOA-244) in Patients With Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04339400",
      "title": "A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms",
      "status": "COMPLETED",
      "last_update": "2026-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04354727",
      "title": "A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy",
      "status": "WITHDRAWN",
      "last_update": "2022-07-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04384692",
      "title": "Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04446650",
      "title": "A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04454658",
      "title": "Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04455841",
      "title": "INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04468984",
      "title": "Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04472598",
      "title": "Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-03-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04480086",
      "title": "Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2023-08-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04485260",
      "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib",
      "status": "UNKNOWN",
      "last_update": "2022-05-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04509700",
      "title": "Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04517851",
      "title": "Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04543279",
      "title": "Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia",
      "status": "TERMINATED",
      "last_update": "2023-12-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04551053",
      "title": "To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04551066",
      "title": "To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)",
      "status": "TERMINATED",
      "last_update": "2025-10-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04562389",
      "title": "Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04562870",
      "title": "A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04603495",
      "title": "Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04629508",
      "title": "To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)",
      "status": "COMPLETED",
      "last_update": "2025-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04640025",
      "title": "A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib",
      "status": "TERMINATED",
      "last_update": "2026-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04676529",
      "title": "Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04717414",
      "title": "An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04817007",
      "title": "A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04851535",
      "title": "Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.",
      "status": "COMPLETED",
      "last_update": "2023-11-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04884191",
      "title": "Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib",
      "status": "COMPLETED",
      "last_update": "2022-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04955938",
      "title": "A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms",
      "status": "WITHDRAWN",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05088356",
      "title": "Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05127174",
      "title": "Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms",
      "status": "TERMINATED",
      "last_update": "2025-12-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05177211",
      "title": "Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)",
      "status": "COMPLETED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05371964",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05393674",
      "title": "Fedratinib in Combination With Nivolumab",
      "status": "COMPLETED",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05447260",
      "title": "A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis",
      "status": "UNKNOWN",
      "last_update": "2022-07-07",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05524857",
      "title": "Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)",
      "status": "TERMINATED",
      "last_update": "2024-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05569538",
      "title": "Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis",
      "status": "UNKNOWN",
      "last_update": "2023-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05936359",
      "title": "A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05982106",
      "title": "To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects",
      "status": "COMPLETED",
      "last_update": "2023-08-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06024915",
      "title": "A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets",
      "status": "COMPLETED",
      "last_update": "2025-12-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06079879",
      "title": "A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06245941",
      "title": "A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)",
      "status": "TERMINATED",
      "last_update": "2026-01-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06290765",
      "title": "Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera",
      "status": "WITHDRAWN",
      "last_update": "2026-07-31",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06388759",
      "title": "TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients",
      "status": "TERMINATED",
      "last_update": "2025-08-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06397313",
      "title": "RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06514807",
      "title": "A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06619522",
      "title": "A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-na\u00efve Patients With Myelofibrosis",
      "status": "WITHDRAWN",
      "last_update": "2025-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06664970",
      "title": "A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2024-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07340138",
      "title": "Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07341048",
      "title": "Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387354",
      "title": "Pacritinib With Aza for Upfront Myelodysplastic Syndrome",
      "status": "WITHDRAWN",
      "last_update": "2026-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07424950",
      "title": "Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07447817",
      "title": "Selinexor and Pacritinib in JAK Inhibitor-na\u00efve MF Patients With Cytopenias",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07498205",
      "title": "Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07521046",
      "title": "Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07529951",
      "title": "Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07679334",
      "title": "Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07722611",
      "title": "A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07734077",
      "title": "Revumenib in Patients With Myelofibrosis",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07750574",
      "title": "Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "JAK2",
     "JAK1",
     "ruxolitinib",
     "Jakafi",
     "fedratinib",
     "Inrebic",
     "pacritinib",
     "Vonjo",
     "momelotinib",
     "Ojjaara"
    ]
   },
   "BET": {
    "n": 11,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05488548",
      "title": "Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-01-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06122831",
      "title": "A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)",
      "status": "RECRUITING",
      "last_update": "2025-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07357727",
      "title": "A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02158858",
      "title": "A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02431260",
      "title": "An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2019-06-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02711137",
      "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03222609",
      "title": "A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04279847",
      "title": "Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04603495",
      "title": "Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06619522",
      "title": "A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-na\u00efve Patients With Myelofibrosis",
      "status": "WITHDRAWN",
      "last_update": "2025-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07340138",
      "title": "Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "BET",
     "pelabresib",
     "CPI-0610"
    ]
   },
   "BCL-xL": {
    "n": 24,
    "n_observational": 2,
    "n_active": 11,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03471260",
      "title": "Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04581512",
      "title": "Study to Evaluate the Safety and Tolerability of EP0042",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04771130",
      "title": "A Study of BGB-11417 in Participants With Myeloid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05074355",
      "title": "Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05641259",
      "title": "A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06479135",
      "title": "Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Na\u00efve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib",
      "status": "RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00049192",
      "title": "Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00933985",
      "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia",
      "status": "TERMINATED",
      "last_update": "2014-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03222609",
      "title": "A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03662126",
      "title": "KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment",
      "status": "UNKNOWN",
      "last_update": "2023-04-28",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03669965",
      "title": "KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2020-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04041050",
      "title": "A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04113616",
      "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)",
      "status": "TERMINATED",
      "last_update": "2024-03-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04454658",
      "title": "Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04468984",
      "title": "Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04472598",
      "title": "Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-03-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04480086",
      "title": "Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2023-08-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04485260",
      "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib",
      "status": "UNKNOWN",
      "last_update": "2022-05-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04640532",
      "title": "KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF",
      "status": "UNKNOWN",
      "last_update": "2022-05-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04835584",
      "title": "KRT-232 and TKI Study in Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04878003",
      "title": "Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Na\u00efve Myelofibrosis",
      "status": "UNKNOWN",
      "last_update": "2022-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04937166",
      "title": "A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-11-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05455294",
      "title": "Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06245941",
      "title": "A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)",
      "status": "TERMINATED",
      "last_update": "2026-01-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "BCL-xL",
     "navitoclax",
     "BCL-2",
     "navtemadlin"
    ]
   },
   "MDM2": {
    "n": 10,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06479135",
      "title": "Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Na\u00efve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib",
      "status": "RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02407080",
      "title": "Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia",
      "status": "COMPLETED",
      "last_update": "2019-09-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03287245",
      "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera",
      "status": "TERMINATED",
      "last_update": "2021-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03662126",
      "title": "KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment",
      "status": "UNKNOWN",
      "last_update": "2023-04-28",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03669965",
      "title": "KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2020-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04113616",
      "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)",
      "status": "TERMINATED",
      "last_update": "2024-03-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04485260",
      "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib",
      "status": "UNKNOWN",
      "last_update": "2022-05-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04640532",
      "title": "KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF",
      "status": "UNKNOWN",
      "last_update": "2022-05-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04835584",
      "title": "KRT-232 and TKI Study in Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04878003",
      "title": "Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Na\u00efve Myelofibrosis",
      "status": "UNKNOWN",
      "last_update": "2022-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "MDM2",
     "navtemadlin",
     "KRT-232",
     "idasanutlin"
    ]
   },
   "interferon": {
    "n": 110,
    "n_observational": 12,
    "n_active": 27,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT04116502",
      "title": "MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04655092",
      "title": "Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients",
      "status": "RECRUITING",
      "last_update": "2024-11-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05535764",
      "title": "AlloHCT With PegINFa for Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05731245",
      "title": "Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2023-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05870475",
      "title": "Pegylated Interferon \u03b1-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV",
      "status": "RECRUITING",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06552429",
      "title": "Peginterferon \u03b1-2b Injection for Hydroxyurea Resistant or Intolerant ET",
      "status": "RECRUITING",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06734637",
      "title": "Efficacy and Safety of Peginterferon in ET and PV.",
      "status": "RECRUITING",
      "last_update": "2024-12-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06770842",
      "title": "Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2025-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07232290",
      "title": "Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07249840",
      "title": "Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07269470",
      "title": "Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07445893",
      "title": "A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV",
      "status": "RECRUITING",
      "last_update": "2026-06-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623200",
      "title": "A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002504",
      "title": "Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2011-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002574",
      "title": "Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002598",
      "title": "Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002761",
      "title": "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2012-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002771",
      "title": "Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-08-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002868",
      "title": "Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-06-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002869",
      "title": "Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003239",
      "title": "Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2012-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003405",
      "title": "Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2021-10-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003408",
      "title": "Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer",
      "status": "COMPLETED",
      "last_update": "2013-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003451",
      "title": "Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003561",
      "title": "Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2011-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003694",
      "title": "Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2013-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003727",
      "title": "Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2019-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004905",
      "title": "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004933",
      "title": "Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa",
      "status": "TERMINATED",
      "last_update": "2016-07-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005948",
      "title": "Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005984",
      "title": "Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005986",
      "title": "Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006053",
      "title": "STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa",
      "status": "COMPLETED",
      "last_update": "2013-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006091",
      "title": "Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment",
      "status": "WITHDRAWN",
      "last_update": "2018-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006343",
      "title": "STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00011934",
      "title": "Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00015847",
      "title": "Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025402",
      "title": "Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-12-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00037882",
      "title": "PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron",
      "status": "TERMINATED",
      "last_update": "2018-11-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00038649",
      "title": "Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C",
      "status": "TERMINATED",
      "last_update": "2018-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00045422",
      "title": "Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00050531",
      "title": "High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2016-05-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00055874",
      "title": "Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-05-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110058",
      "title": "Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00146913",
      "title": "AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year",
      "status": "UNKNOWN",
      "last_update": "2007-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171223",
      "title": "An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha",
      "status": "COMPLETED",
      "last_update": "2021-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00219739",
      "title": "STI571 ProspectIve RandomIzed Trial: SPIRIT",
      "status": "COMPLETED",
      "last_update": "2020-04-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00241241",
      "title": "Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera",
      "status": "COMPLETED",
      "last_update": "2015-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00297570",
      "title": "Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy",
      "status": "UNKNOWN",
      "last_update": "2007-10-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00303290",
      "title": "PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML",
      "status": "COMPLETED",
      "last_update": "2015-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00333840",
      "title": "Safety and Efficacy of Imatinib Versus Interferon-\u03b1 Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-10-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00363649",
      "title": "Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI",
      "status": "COMPLETED",
      "last_update": "2018-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00390897",
      "title": "Glivec\u00ae (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec\u00ae-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2008-11-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00415857",
      "title": "Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)",
      "status": "TERMINATED",
      "last_update": "2018-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00452023",
      "title": "Pegasys\u00ae in Patients With Myeloproliferative Diseases",
      "status": "COMPLETED",
      "last_update": "2024-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00511121",
      "title": "Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)",
      "status": "TERMINATED",
      "last_update": "2007-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00511303",
      "title": "Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2007-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00573378",
      "title": "Imatinib or Nilotinib With Pegylated Interferon-\u03b12b in Chronic Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2023-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00763763",
      "title": "Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive",
      "status": "COMPLETED",
      "last_update": "2011-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01193699",
      "title": "Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera",
      "status": "COMPLETED",
      "last_update": "2018-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01220648",
      "title": "Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)",
      "status": "COMPLETED",
      "last_update": "2015-05-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01227356",
      "title": "A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-10-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01259817",
      "title": "Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)",
      "status": "COMPLETED",
      "last_update": "2017-01-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01259856",
      "title": "Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)",
      "status": "COMPLETED",
      "last_update": "2019-04-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01294618",
      "title": "Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2019-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01387763",
      "title": "A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms",
      "status": "COMPLETED",
      "last_update": "2022-04-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01392170",
      "title": "Pegasys in Patients With Chronic Myeloid Leukemia (CML)",
      "status": "TERMINATED",
      "last_update": "2015-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01657604",
      "title": "TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study",
      "status": "COMPLETED",
      "last_update": "2023-05-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01725204",
      "title": "Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01758588",
      "title": "Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2018-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01866553",
      "title": "Nilotinib Plus Pegylated Interferon-\u03b12b in CML",
      "status": "TERMINATED",
      "last_update": "2018-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01933906",
      "title": "Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response",
      "status": "COMPLETED",
      "last_update": "2019-01-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01949805",
      "title": "Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera",
      "status": "COMPLETED",
      "last_update": "2016-11-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02001818",
      "title": "Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia",
      "status": "COMPLETED",
      "last_update": "2024-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02038036",
      "title": "Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.",
      "status": "COMPLETED",
      "last_update": "2021-07-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02101268",
      "title": "Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF",
      "status": "COMPLETED",
      "last_update": "2023-05-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02201459",
      "title": "Nilotinib \u00b1 Peg-IFN for First Line Chronic Phase CML Patients",
      "status": "COMPLETED",
      "last_update": "2025-10-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02218047",
      "title": "AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.",
      "status": "COMPLETED",
      "last_update": "2021-06-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02370329",
      "title": "P1101 in Treating Patients With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2025-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02381379",
      "title": "Malaysia Stop Tyrosine Kinase Inhibitor Trial",
      "status": "UNKNOWN",
      "last_update": "2020-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02407080",
      "title": "Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia",
      "status": "COMPLETED",
      "last_update": "2019-09-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02523638",
      "title": "Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients",
      "status": "COMPLETED",
      "last_update": "2016-02-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02577926",
      "title": "The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02736721",
      "title": "Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2016-09-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02742324",
      "title": "Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg",
      "status": "COMPLETED",
      "last_update": "2022-07-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02829775",
      "title": "A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys\u00ae) or Recombinant Interferon Alfa-2a (Roferon-A\u00ae) in Prior Clinical Studies",
      "status": "COMPLETED",
      "last_update": "2017-01-09",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03003325",
      "title": "The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03547154",
      "title": "Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^\u00ae A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)",
      "status": "TERMINATED",
      "last_update": "2019-08-12",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03831776",
      "title": "Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04126681",
      "title": "A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04182100",
      "title": "Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply",
      "status": "COMPLETED",
      "last_update": "2025-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04226950",
      "title": "Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia",
      "status": "UNKNOWN",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04285086",
      "title": "Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04562870",
      "title": "A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04576156",
      "title": "A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04988815",
      "title": "Ropeginterferon Alfa 2b for Early Myelofibrosis",
      "status": "UNKNOWN",
      "last_update": "2022-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05400122",
      "title": "Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer",
      "status": "SUSPENDED",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05481151",
      "title": "A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05482971",
      "title": "A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05485948",
      "title": "A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06002490",
      "title": "A Study to Evaluate P1101 in Japanese PV Patients",
      "status": "COMPLETED",
      "last_update": "2024-11-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06079879",
      "title": "A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06290765",
      "title": "Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera",
      "status": "WITHDRAWN",
      "last_update": "2026-07-31",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06468033",
      "title": "P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06514807",
      "title": "A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07105319",
      "title": "Ropeginterferon for Treatment Free Remission",
      "status": "COMPLETED",
      "last_update": "2025-08-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07468916",
      "title": "Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07521046",
      "title": "Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07722611",
      "title": "A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07734272",
      "title": "Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "interferon",
     "ropeginterferon",
     "Besremi",
     "peginterferon"
    ]
   },
   "hepcidin": {
    "n": 7,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07648030",
      "title": "A Study of Rusfertide in Japanese Adults With Polycythemia Vera",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04057040",
      "title": "Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)",
      "status": "COMPLETED",
      "last_update": "2025-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04173494",
      "title": "A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)",
      "status": "COMPLETED",
      "last_update": "2023-11-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04767802",
      "title": "PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05210790",
      "title": "A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06033586",
      "title": "Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07765602",
      "title": "A Study of Rusfertide in Adults With Polycythemia Vera in China",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "hepcidin",
     "rusfertide",
     "PTG-300"
    ]
   },
   "CALR": {
    "n": 10,
    "n_observational": 3,
    "n_active": 9,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04942080",
      "title": "Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)",
      "status": "RECRUITING",
      "last_update": "2026-03-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025488",
      "title": "Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm",
      "status": "RECRUITING",
      "last_update": "2025-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06034002",
      "title": "A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06150157",
      "title": "A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07008118",
      "title": "A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623200",
      "title": "A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03566446",
      "title": "CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms",
      "status": "COMPLETED",
      "last_update": "2023-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04285086",
      "title": "Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05936359",
      "title": "A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06514807",
      "title": "A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CALR",
     "mutant calreticulin",
     "INCA033989",
     "JNJ-88549968"
    ]
   },
   "LSD1": {
    "n": 15,
    "n_observational": 0,
    "n_active": 9,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06351631",
      "title": "A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07612280",
      "title": "Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis",
      "status": "RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02712905",
      "title": "An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-11-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03136185",
      "title": "Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)",
      "status": "COMPLETED",
      "last_update": "2024-01-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04081220",
      "title": "Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04254978",
      "title": "Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)",
      "status": "COMPLETED",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04262141",
      "title": "IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04734990",
      "title": "Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05223920",
      "title": "An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)",
      "status": "COMPLETED",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05558696",
      "title": "A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)",
      "status": "COMPLETED",
      "last_update": "2026-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05569538",
      "title": "Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis",
      "status": "UNKNOWN",
      "last_update": "2023-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06079879",
      "title": "A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06456346",
      "title": "Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07424950",
      "title": "Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07722611",
      "title": "A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "LSD1",
     "bomedemstat"
    ]
   },
   "PI3K": {
    "n": 5,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02718300",
      "title": "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2024-05-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04509700",
      "title": "Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04551053",
      "title": "To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04551066",
      "title": "To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)",
      "status": "TERMINATED",
      "last_update": "2025-10-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PI3K",
     "parsaclisib"
    ]
   },
   "telomerase": {
    "n": 7,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06247787",
      "title": "A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01243073",
      "title": "Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera",
      "status": "COMPLETED",
      "last_update": "2016-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01731951",
      "title": "Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2021-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02426086",
      "title": "Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor",
      "status": "COMPLETED",
      "last_update": "2021-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04576156",
      "title": "A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05371964",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07549451",
      "title": "Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "telomerase",
     "imetelstat",
     "Rytelo"
    ]
   },
   "hydroxyurea": {
    "n": 248,
    "n_observational": 18,
    "n_active": 43,
    "n_withdrawn": 8,
    "trials": [
     {
      "nct": "NCT02727803",
      "title": "Personalized NK Cell Therapy in CBT",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03314974",
      "title": "Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03810196",
      "title": "CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCR\u03b1\u03b2/CD19 Depleted HSCT",
      "status": "RECRUITING",
      "last_update": "2026-07-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03970096",
      "title": "Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)",
      "status": "RECRUITING",
      "last_update": "2026-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116502",
      "title": "MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644016",
      "title": "Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04708054",
      "title": "Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05564390",
      "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05735717",
      "title": "MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05870475",
      "title": "Pegylated Interferon \u03b1-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV",
      "status": "RECRUITING",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06093672",
      "title": "Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera",
      "status": "RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06315309",
      "title": "Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant",
      "status": "RECRUITING",
      "last_update": "2025-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06345495",
      "title": "High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06477549",
      "title": "BeFluBu vs FluBuRux Conditioning in Haploidentical HCT",
      "status": "RECRUITING",
      "last_update": "2024-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06552429",
      "title": "Peginterferon \u03b1-2b Injection for Hydroxyurea Resistant or Intolerant ET",
      "status": "RECRUITING",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06674382",
      "title": "Haplo-HSCT for Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06786234",
      "title": "A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial",
      "status": "RECRUITING",
      "last_update": "2026-06-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06802315",
      "title": "Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)",
      "status": "RECRUITING",
      "last_update": "2026-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859424",
      "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07033598",
      "title": "Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07228624",
      "title": "Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07232290",
      "title": "Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07565220",
      "title": "Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07588594",
      "title": "Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002502",
      "title": "Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2013-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002547",
      "title": "Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2012-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002549",
      "title": "Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2009-12-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002592",
      "title": "Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2015-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002674",
      "title": "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002761",
      "title": "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2012-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002768",
      "title": "Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission",
      "status": "COMPLETED",
      "last_update": "2016-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002771",
      "title": "Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-08-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002789",
      "title": "Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-03-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002792",
      "title": "Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders",
      "status": "COMPLETED",
      "last_update": "2010-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002798",
      "title": "Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2013-01-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002831",
      "title": "Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-10-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002868",
      "title": "Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-06-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002869",
      "title": "Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003116",
      "title": "High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2010-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003270",
      "title": "Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2019-12-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003335",
      "title": "Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2012-03-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003336",
      "title": "Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions",
      "status": "COMPLETED",
      "last_update": "2010-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003619",
      "title": "Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003661",
      "title": "Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2011-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003816",
      "title": "Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-13",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003913",
      "title": "Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease",
      "status": "COMPLETED",
      "last_update": "2010-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003960",
      "title": "Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-05-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004128",
      "title": "Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2009-12-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004181",
      "title": "Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia",
      "status": "COMPLETED",
      "last_update": "2012-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004896",
      "title": "Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2012-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004899",
      "title": "Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2012-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004933",
      "title": "Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa",
      "status": "TERMINATED",
      "last_update": "2016-07-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005641",
      "title": "Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation",
      "status": "TERMINATED",
      "last_update": "2012-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005797",
      "title": "Bone Marrow Transplant in Treating Patients With Hematologic Cancers",
      "status": "COMPLETED",
      "last_update": "2020-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005823",
      "title": "Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2013-12-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005866",
      "title": "S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2015-03-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005948",
      "title": "Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2010-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005986",
      "title": "Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006363",
      "title": "Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006367",
      "title": "Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2010-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00014469",
      "title": "Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025402",
      "title": "Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia",
      "status": "UNKNOWN",
      "last_update": "2013-12-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00027924",
      "title": "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2010-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00049634",
      "title": "Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder",
      "status": "COMPLETED",
      "last_update": "2010-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00053196",
      "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054327",
      "title": "Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054340",
      "title": "Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder",
      "status": "COMPLETED",
      "last_update": "2010-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00055653",
      "title": "Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders",
      "status": "COMPLETED",
      "last_update": "2011-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00055874",
      "title": "Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-05-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00060255",
      "title": "High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2013-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070135",
      "title": "Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission",
      "status": "COMPLETED",
      "last_update": "2018-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00077116",
      "title": "Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2012-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00081055",
      "title": "OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2014-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00083187",
      "title": "VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia",
      "status": "COMPLETED",
      "last_update": "2013-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00084695",
      "title": "Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00134017",
      "title": "Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2018-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00167219",
      "title": "Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)",
      "status": "COMPLETED",
      "last_update": "2023-11-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00175838",
      "title": "Primary Thrombocythaemia 1 Trial",
      "status": "COMPLETED",
      "last_update": "2017-01-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00176930",
      "title": "Stem Cell Transplant for Hematological Malignancy",
      "status": "TERMINATED",
      "last_update": "2021-01-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00179764",
      "title": "Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])",
      "status": "COMPLETED",
      "last_update": "2019-08-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00186342",
      "title": "Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2012-12-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00202644",
      "title": "A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients",
      "status": "COMPLETED",
      "last_update": "2021-06-02",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00245037",
      "title": "Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00245115",
      "title": "Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia",
      "status": "TERMINATED",
      "last_update": "2018-08-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00248547",
      "title": "Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2017-05-09",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00253552",
      "title": "G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders",
      "status": "TERMINATED",
      "last_update": "2012-05-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00281879",
      "title": "Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2017-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00290628",
      "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2017-11-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295997",
      "title": "Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia",
      "status": "UNKNOWN",
      "last_update": "2014-01-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00296023",
      "title": "Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2012-10-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00301834",
      "title": "Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders",
      "status": "COMPLETED",
      "last_update": "2017-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00301912",
      "title": "Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",
      "status": "WITHDRAWN",
      "last_update": "2012-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00301951",
      "title": "Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-10-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00304018",
      "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-08-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00305708",
      "title": "Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission",
      "status": "COMPLETED",
      "last_update": "2012-11-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00322101",
      "title": "Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-10-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00333840",
      "title": "Safety and Efficacy of Imatinib Versus Interferon-\u03b1 Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-10-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00346359",
      "title": "Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer",
      "status": "COMPLETED",
      "last_update": "2010-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00361140",
      "title": "Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)",
      "status": "COMPLETED",
      "last_update": "2017-03-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00402558",
      "title": "Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",
      "status": "COMPLETED",
      "last_update": "2015-05-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00413634",
      "title": "The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)",
      "status": "COMPLETED",
      "last_update": "2021-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00445744",
      "title": "Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2018-01-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00446173",
      "title": "Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2015-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00448201",
      "title": "Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease",
      "status": "COMPLETED",
      "last_update": "2017-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00448357",
      "title": "Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen",
      "status": "COMPLETED",
      "last_update": "2017-07-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00454480",
      "title": "Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",
      "status": "COMPLETED",
      "last_update": "2013-08-26",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00469014",
      "title": "Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00475020",
      "title": "Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2019-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00481052",
      "title": "Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2022-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00499889",
      "title": "Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients",
      "status": "TERMINATED",
      "last_update": "2012-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00513474",
      "title": "Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2017-05-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00516152",
      "title": "Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT",
      "status": "COMPLETED",
      "last_update": "2009-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00521430",
      "title": "Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease",
      "status": "COMPLETED",
      "last_update": "2013-03-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00531310",
      "title": "Reduced Intensity AlloSCT in(CML) With Persistent Disease",
      "status": "TERMINATED",
      "last_update": "2011-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00534430",
      "title": "Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2026-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00534469",
      "title": "Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R",
      "status": "COMPLETED",
      "last_update": "2025-12-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00540995",
      "title": "Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer",
      "status": "TERMINATED",
      "last_update": "2023-11-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00544115",
      "title": "Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00547196",
      "title": "AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders",
      "status": "COMPLETED",
      "last_update": "2024-06-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00555048",
      "title": "Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2017-05-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00579111",
      "title": "Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)",
      "status": "TERMINATED",
      "last_update": "2016-05-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00611351",
      "title": "Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2023-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00619645",
      "title": "Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers",
      "status": "COMPLETED",
      "last_update": "2018-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00627666",
      "title": "Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer",
      "status": "COMPLETED",
      "last_update": "2013-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00669890",
      "title": "Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML",
      "status": "TERMINATED",
      "last_update": "2015-04-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691015",
      "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2017-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00726232",
      "title": "Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia",
      "status": "TERMINATED",
      "last_update": "2025-10-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00732316",
      "title": "Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome",
      "status": "COMPLETED",
      "last_update": "2012-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00740467",
      "title": "Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders",
      "status": "UNKNOWN",
      "last_update": "2010-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00782379",
      "title": "Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00787761",
      "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer",
      "status": "COMPLETED",
      "last_update": "2012-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00806767",
      "title": "Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer",
      "status": "COMPLETED",
      "last_update": "2011-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00809276",
      "title": "Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY",
      "status": "COMPLETED",
      "last_update": "2015-02-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00813124",
      "title": "Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)",
      "status": "COMPLETED",
      "last_update": "2021-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00818961",
      "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2013-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00822770",
      "title": "Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin",
      "status": "COMPLETED",
      "last_update": "2020-10-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00928707",
      "title": "Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera",
      "status": "COMPLETED",
      "last_update": "2019-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00940784",
      "title": "Clopidogrel and Aspirin for the Treatment of Polycythemia Vera",
      "status": "WITHDRAWN",
      "last_update": "2014-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00966810",
      "title": "Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion",
      "status": "UNKNOWN",
      "last_update": "2009-08-27",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00988013",
      "title": "Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-06-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00997386",
      "title": "Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States",
      "status": "COMPLETED",
      "last_update": "2019-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01003054",
      "title": "Autologous Transplantation for Chronic Myelogenous Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01015742",
      "title": "Unrelated Double Umbilical Cord Blood Units Transplantation",
      "status": "UNKNOWN",
      "last_update": "2012-06-04",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01020539",
      "title": "Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01020734",
      "title": "Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission",
      "status": "COMPLETED",
      "last_update": "2015-12-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01044745",
      "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2023-09-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01050946",
      "title": "Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit",
      "status": "TERMINATED",
      "last_update": "2015-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01056614",
      "title": "Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies",
      "status": "COMPLETED",
      "last_update": "2016-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01065038",
      "title": "Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia",
      "status": "COMPLETED",
      "last_update": "2010-10-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01093586",
      "title": "Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2019-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01114087",
      "title": "Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility",
      "status": "COMPLETED",
      "last_update": "2011-03-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01118013",
      "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01135329",
      "title": "Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers",
      "status": "TERMINATED",
      "last_update": "2026-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01158118",
      "title": "Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors",
      "status": "COMPLETED",
      "last_update": "2017-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01168219",
      "title": "Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01177371",
      "title": "High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2010-08-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01214915",
      "title": "Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia",
      "status": "COMPLETED",
      "last_update": "2021-06-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01230775",
      "title": "Anagrelide Retard vs. Placebo: Efficacy and Safety in \"At-risk\" Patients With Essential Thrombocythaemia",
      "status": "COMPLETED",
      "last_update": "2016-05-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01243944",
      "title": "Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)",
      "status": "COMPLETED",
      "last_update": "2019-03-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01244906",
      "title": "Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant",
      "status": "COMPLETED",
      "last_update": "2015-05-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01259817",
      "title": "Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)",
      "status": "COMPLETED",
      "last_update": "2017-01-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01259856",
      "title": "Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)",
      "status": "COMPLETED",
      "last_update": "2019-04-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01338987",
      "title": "Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation",
      "status": "COMPLETED",
      "last_update": "2021-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01339988",
      "title": "Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)",
      "status": "UNKNOWN",
      "last_update": "2011-04-21",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01364363",
      "title": "Unrelated Donor Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2022-11-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01366612",
      "title": "Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation",
      "status": "TERMINATED",
      "last_update": "2026-04-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01384513",
      "title": "A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01387763",
      "title": "A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms",
      "status": "COMPLETED",
      "last_update": "2022-04-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01390402",
      "title": "Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG",
      "status": "COMPLETED",
      "last_update": "2016-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01427881",
      "title": "Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01467661",
      "title": "Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia",
      "status": "COMPLETED",
      "last_update": "2021-06-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01471067",
      "title": "Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01499147",
      "title": "Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2018-11-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01500161",
      "title": "Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match",
      "status": "TERMINATED",
      "last_update": "2013-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01572662",
      "title": "Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning",
      "status": "COMPLETED",
      "last_update": "2023-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01621477",
      "title": "T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant",
      "status": "TERMINATED",
      "last_update": "2017-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01622556",
      "title": "Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2014-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01632904",
      "title": "Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study",
      "status": "COMPLETED",
      "last_update": "2017-11-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01645124",
      "title": "Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)",
      "status": "TERMINATED",
      "last_update": "2012-07-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01663766",
      "title": "Phase I Study of Milatuzumab for Graft Versus Host Disease",
      "status": "TERMINATED",
      "last_update": "2021-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01668173",
      "title": "HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET",
      "status": "TERMINATED",
      "last_update": "2016-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01696461",
      "title": "A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor",
      "status": "COMPLETED",
      "last_update": "2023-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01760655",
      "title": "Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01773395",
      "title": "GVAX vs. Placebo for MDS/AML After Allo HSCT",
      "status": "TERMINATED",
      "last_update": "2022-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01800643",
      "title": "Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation",
      "status": "UNKNOWN",
      "last_update": "2014-12-03",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01814475",
      "title": "Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2021-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01823198",
      "title": "Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-11-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01824693",
      "title": "Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01949805",
      "title": "Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera",
      "status": "COMPLETED",
      "last_update": "2016-11-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02038036",
      "title": "Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.",
      "status": "COMPLETED",
      "last_update": "2021-07-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02061800",
      "title": "CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant",
      "status": "UNKNOWN",
      "last_update": "2024-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02076815",
      "title": "Anagrelide Retard in Essential Thrombocythemia",
      "status": "COMPLETED",
      "last_update": "2015-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02084563",
      "title": "Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms",
      "status": "COMPLETED",
      "last_update": "2016-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02101268",
      "title": "Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF",
      "status": "COMPLETED",
      "last_update": "2023-05-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02120157",
      "title": "Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02125318",
      "title": "A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders",
      "status": "COMPLETED",
      "last_update": "2017-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02129582",
      "title": "Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-05-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02158858",
      "title": "A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02251821",
      "title": "JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02292446",
      "title": "Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.",
      "status": "COMPLETED",
      "last_update": "2019-07-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02410551",
      "title": "Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)",
      "status": "TERMINATED",
      "last_update": "2018-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02469974",
      "title": "Ruxolitinib in Combination With Autotransplant",
      "status": "WITHDRAWN",
      "last_update": "2016-08-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02480608",
      "title": "Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)",
      "status": "COMPLETED",
      "last_update": "2015-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02493530",
      "title": "TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea",
      "status": "COMPLETED",
      "last_update": "2026-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02577926",
      "title": "The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02611973",
      "title": "Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia",
      "status": "UNKNOWN",
      "last_update": "2017-07-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02627573",
      "title": "Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT",
      "status": "TERMINATED",
      "last_update": "2019-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02660281",
      "title": "URMC Related Haplo-identical Donor BMT",
      "status": "COMPLETED",
      "last_update": "2021-11-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02743351",
      "title": "Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-02-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02806375",
      "title": "PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2019-04-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02861417",
      "title": "Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02916979",
      "title": "Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG",
      "status": "COMPLETED",
      "last_update": "2023-10-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02962388",
      "title": "The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line",
      "status": "TERMINATED",
      "last_update": "2021-06-29",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03018223",
      "title": "Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT",
      "status": "COMPLETED",
      "last_update": "2021-09-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03096782",
      "title": "Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-10-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03123588",
      "title": "Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)",
      "status": "TERMINATED",
      "last_update": "2021-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03128359",
      "title": "High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2024-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03165734",
      "title": "A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03232177",
      "title": "Anagre Cap. in Patients With High-Risk Essential Thrombocythemia",
      "status": "COMPLETED",
      "last_update": "2021-07-21",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03287245",
      "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera",
      "status": "TERMINATED",
      "last_update": "2021-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03303950",
      "title": "Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2022-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03515018",
      "title": "Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients",
      "status": "UNKNOWN",
      "last_update": "2018-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03547154",
      "title": "Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^\u00ae A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)",
      "status": "TERMINATED",
      "last_update": "2019-08-12",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03602898",
      "title": "Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "status": "WITHDRAWN",
      "last_update": "2021-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03613532",
      "title": "Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03615105",
      "title": "Donor Stem Cell Transplantation Using \u03b1/\u03b2+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors",
      "status": "TERMINATED",
      "last_update": "2025-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03662126",
      "title": "KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment",
      "status": "UNKNOWN",
      "last_update": "2023-04-28",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03674411",
      "title": "Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03779854",
      "title": "Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04126681",
      "title": "A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04151706",
      "title": "CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML",
      "status": "COMPLETED",
      "last_update": "2024-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04282174",
      "title": "CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2022-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04285086",
      "title": "Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04384692",
      "title": "Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04451200",
      "title": "Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2020-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04562870",
      "title": "A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04576156",
      "title": "A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04617028",
      "title": "Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2023-11-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04904588",
      "title": "HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04942730",
      "title": "Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)",
      "status": "COMPLETED",
      "last_update": "2024-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05005182",
      "title": "Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05485948",
      "title": "A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05589896",
      "title": "A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05853458",
      "title": "Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors",
      "status": "TERMINATED",
      "last_update": "2026-08-18",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06001385",
      "title": "HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06079879",
      "title": "A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06456346",
      "title": "Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07722611",
      "title": "A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 6,
     "n_observational": 0,
     "n_active": 2,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT02727803",
       "title": "Personalized NK Cell Therapy in CBT",
       "status": "RECRUITING",
       "last_update": "2026-07-30",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03810196",
       "title": "CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCR\u03b1\u03b2/CD19 Depleted HSCT",
       "status": "RECRUITING",
       "last_update": "2026-07-08",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00005641",
       "title": "Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation",
       "status": "TERMINATED",
       "last_update": "2012-12-11",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00402558",
       "title": "Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",
       "status": "COMPLETED",
       "last_update": "2015-05-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00806767",
       "title": "Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer",
       "status": "COMPLETED",
       "last_update": "2011-05-17",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03615105",
       "title": "Donor Stem Cell Transplantation Using \u03b1/\u03b2+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors",
       "status": "TERMINATED",
       "last_update": "2025-04-06",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "hydroxyurea",
     "anagrelide",
     "busulfan"
    ]
   }
  },
  "by_drug": {
   "AT-9283": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00522990",
      "title": "Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias",
      "status": "TERMINATED",
      "last_update": "2024-08-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AZD-1480": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00910728",
      "title": "Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases",
      "status": "COMPLETED",
      "last_update": "2017-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ELTROMBOPAG": {
    "n": 10,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06345495",
      "title": "High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00961064",
      "title": "A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)",
      "status": "COMPLETED",
      "last_update": "2023-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01428635",
      "title": "Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy",
      "status": "COMPLETED",
      "last_update": "2023-09-26",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01440374",
      "title": "A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01550185",
      "title": "Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01772420",
      "title": "Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia",
      "status": "COMPLETED",
      "last_update": "2023-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02010645",
      "title": "Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)",
      "status": "TERMINATED",
      "last_update": "2020-01-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02071901",
      "title": "Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2026-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02323178",
      "title": "A Study of Eltrombopag in Patients With CMML and Thrombocytopenia",
      "status": "COMPLETED",
      "last_update": "2021-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06630221",
      "title": "Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations",
      "status": "SUSPENDED",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ELTROMBOPAG OLAMINE": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01428635",
      "title": "Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy",
      "status": "COMPLETED",
      "last_update": "2023-09-26",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01550185",
      "title": "Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01772420",
      "title": "Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia",
      "status": "COMPLETED",
      "last_update": "2023-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02071901",
      "title": "Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2026-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ENASIDENIB": {
    "n": 9,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03383575",
      "title": "Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03683433",
      "title": "Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05564390",
      "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03515512",
      "title": "IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2025-10-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04281498",
      "title": "Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04522895",
      "title": "IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04603001",
      "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04955938",
      "title": "A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms",
      "status": "WITHDRAWN",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "EPRENETAPOPT": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03072043",
      "title": "Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms",
      "status": "COMPLETED",
      "last_update": "2022-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03588078",
      "title": "Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine",
      "status": "UNKNOWN",
      "last_update": "2020-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FEDRATINIB": {
    "n": 17,
    "n_observational": 4,
    "n_active": 6,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04282187",
      "title": "Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04370301",
      "title": "Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00631462",
      "title": "A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2009-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00724334",
      "title": "A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2025-03-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01692366",
      "title": "Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly",
      "status": "COMPLETED",
      "last_update": "2025-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03755518",
      "title": "A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib",
      "status": "TERMINATED",
      "last_update": "2024-12-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03952039",
      "title": "An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib",
      "status": "COMPLETED",
      "last_update": "2025-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04446650",
      "title": "A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04562870",
      "title": "A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04629508",
      "title": "To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)",
      "status": "COMPLETED",
      "last_update": "2025-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04817007",
      "title": "A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04955938",
      "title": "A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms",
      "status": "WITHDRAWN",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05127174",
      "title": "Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms",
      "status": "TERMINATED",
      "last_update": "2025-12-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05177211",
      "title": "Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)",
      "status": "COMPLETED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05393674",
      "title": "Fedratinib in Combination With Nivolumab",
      "status": "COMPLETED",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05524857",
      "title": "Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)",
      "status": "TERMINATED",
      "last_update": "2024-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07734077",
      "title": "Revumenib in Patients With Myelofibrosis",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IDASANUTLIN": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02407080",
      "title": "Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia",
      "status": "COMPLETED",
      "last_update": "2019-09-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03287245",
      "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera",
      "status": "TERMINATED",
      "last_update": "2021-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LESTAURTINIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00494585",
      "title": "CEP-701 for PH-negative Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2012-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00586651",
      "title": "Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis",
      "status": "COMPLETED",
      "last_update": "2015-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00668421",
      "title": "CEP-701 (Lestaurtinib) in Myelofibrosis",
      "status": "UNKNOWN",
      "last_update": "2014-11-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MOMELOTINIB": {
    "n": 20,
    "n_observational": 2,
    "n_active": 11,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04176198",
      "title": "A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05488548",
      "title": "Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-01-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05980806",
      "title": "A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-na\u00efve Myelofibrosis and Moderate Thrombocytopenia",
      "status": "RECRUITING",
      "last_update": "2026-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06150157",
      "title": "A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06517875",
      "title": "Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07071155",
      "title": "Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-03-27",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07104799",
      "title": "Momelotinib During and After HCT in Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00935987",
      "title": "Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)",
      "status": "COMPLETED",
      "last_update": "2019-02-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01236638",
      "title": "Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)",
      "status": "COMPLETED",
      "last_update": "2019-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01423058",
      "title": "Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2019-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01969838",
      "title": "Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2023-05-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01998828",
      "title": "Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia",
      "status": "TERMINATED",
      "last_update": "2020-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02101268",
      "title": "Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF",
      "status": "COMPLETED",
      "last_update": "2023-05-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02124746",
      "title": "Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia",
      "status": "COMPLETED",
      "last_update": "2023-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02515630",
      "title": "Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)",
      "status": "COMPLETED",
      "last_update": "2023-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03441113",
      "title": "Extended Access of Momelotinib in Adults With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04173494",
      "title": "A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)",
      "status": "COMPLETED",
      "last_update": "2023-11-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07424950",
      "title": "Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07498205",
      "title": "Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07734077",
      "title": "Revumenib in Patients With Myelofibrosis",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAVTEMADLIN": {
    "n": 8,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06479135",
      "title": "Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Na\u00efve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib",
      "status": "RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03662126",
      "title": "KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment",
      "status": "UNKNOWN",
      "last_update": "2023-04-28",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03669965",
      "title": "KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2020-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04113616",
      "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)",
      "status": "TERMINATED",
      "last_update": "2024-03-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04485260",
      "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib",
      "status": "UNKNOWN",
      "last_update": "2022-05-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04640532",
      "title": "KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF",
      "status": "UNKNOWN",
      "last_update": "2022-05-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04835584",
      "title": "KRT-232 and TKI Study in Chronic Myeloid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04878003",
      "title": "Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Na\u00efve Myelofibrosis",
      "status": "UNKNOWN",
      "last_update": "2022-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NS-018": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01423851",
      "title": "Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF",
      "status": "COMPLETED",
      "last_update": "2022-03-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04854096",
      "title": "Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2025-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PACRITINIB": {
    "n": 23,
    "n_observational": 1,
    "n_active": 13,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT04282187",
      "title": "Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05980806",
      "title": "A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-na\u00efve Myelofibrosis and Moderate Thrombocytopenia",
      "status": "RECRUITING",
      "last_update": "2026-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06159491",
      "title": "Pacritinib in CMML",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06218628",
      "title": "Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition",
      "status": "RECRUITING",
      "last_update": "2024-05-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06303193",
      "title": "Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06414681",
      "title": "Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined",
      "status": "RECRUITING",
      "last_update": "2026-05-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07033598",
      "title": "Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07148947",
      "title": "Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07394153",
      "title": "Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01773187",
      "title": "Pacritinib Versus Best Available Therapy to Treat Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2020-09-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02055781",
      "title": "Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia",
      "status": "TERMINATED",
      "last_update": "2021-11-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02410551",
      "title": "Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)",
      "status": "TERMINATED",
      "last_update": "2018-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02564536",
      "title": "Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)",
      "status": "WITHDRAWN",
      "last_update": "2017-05-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02584777",
      "title": "A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis",
      "status": "WITHDRAWN",
      "last_update": "2021-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02765724",
      "title": "Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects",
      "status": "COMPLETED",
      "last_update": "2020-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02807077",
      "title": "PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects",
      "status": "COMPLETED",
      "last_update": "2018-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03165734",
      "title": "A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03645824",
      "title": "Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2022-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04884191",
      "title": "Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib",
      "status": "COMPLETED",
      "last_update": "2022-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387354",
      "title": "Pacritinib With Aza for Upfront Myelodysplastic Syndrome",
      "status": "WITHDRAWN",
      "last_update": "2026-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07447817",
      "title": "Selinexor and Pacritinib in JAK Inhibitor-na\u00efve MF Patients With Cytopenias",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07679334",
      "title": "Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ROMIPLOSTIM": {
    "n": 1,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06345495",
      "title": "High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RUXOLITINIB": {
    "n": 160,
    "n_observational": 18,
    "n_active": 60,
    "n_withdrawn": 6,
    "trials": [
     {
      "nct": "NCT04116502",
      "title": "MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04176198",
      "title": "A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04282187",
      "title": "Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04370301",
      "title": "Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644211",
      "title": "Ruxolitinib in Thrombocythemia and Polycythemia Vera",
      "status": "RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05037760",
      "title": "A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05280509",
      "title": "Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Na\u00efve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib",
      "status": "RECRUITING",
      "last_update": "2023-02-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05423691",
      "title": "Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs",
      "status": "RECRUITING",
      "last_update": "2025-04-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05488548",
      "title": "Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-01-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05817955",
      "title": "Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN",
      "status": "RECRUITING",
      "last_update": "2023-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05870475",
      "title": "Pegylated Interferon \u03b1-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV",
      "status": "RECRUITING",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05980806",
      "title": "A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-na\u00efve Myelofibrosis and Moderate Thrombocytopenia",
      "status": "RECRUITING",
      "last_update": "2026-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06034002",
      "title": "A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06150157",
      "title": "A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06291987",
      "title": "Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06327100",
      "title": "Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)",
      "status": "RECRUITING",
      "last_update": "2026-05-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06345495",
      "title": "High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06477549",
      "title": "BeFluBu vs FluBuRux Conditioning in Haploidentical HCT",
      "status": "RECRUITING",
      "last_update": "2024-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06479135",
      "title": "Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Na\u00efve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib",
      "status": "RECRUITING",
      "last_update": "2025-09-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06770842",
      "title": "Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2025-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06773195",
      "title": "A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859424",
      "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06887803",
      "title": "A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors",
      "status": "RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07128381",
      "title": "Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07228624",
      "title": "Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07238712",
      "title": "Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor",
      "status": "RECRUITING",
      "last_update": "2025-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07249346",
      "title": "Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07357727",
      "title": "A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623161",
      "title": "A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00509899",
      "title": "Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2018-03-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00674479",
      "title": "INCB018424 in Patients With Advanced Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00726232",
      "title": "Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia",
      "status": "TERMINATED",
      "last_update": "2025-10-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00934544",
      "title": "Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial",
      "status": "COMPLETED",
      "last_update": "2019-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00952289",
      "title": "COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial",
      "status": "COMPLETED",
      "last_update": "2018-03-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01164163",
      "title": "INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",
      "status": "COMPLETED",
      "last_update": "2014-10-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01243944",
      "title": "Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)",
      "status": "COMPLETED",
      "last_update": "2019-03-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01317875",
      "title": "Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)",
      "status": "COMPLETED",
      "last_update": "2025-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01340651",
      "title": "Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients",
      "status": "COMPLETED",
      "last_update": "2014-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01348490",
      "title": "Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)",
      "status": "COMPLETED",
      "last_update": "2020-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01369498",
      "title": "Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2020-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01375140",
      "title": "Ruxolitinib and Lenalidomide for Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01392443",
      "title": "Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF",
      "status": "COMPLETED",
      "last_update": "2019-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01433445",
      "title": "Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2021-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01445769",
      "title": "Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2019-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01493414",
      "title": "INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.",
      "status": "COMPLETED",
      "last_update": "2019-04-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01558739",
      "title": "Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)",
      "status": "COMPLETED",
      "last_update": "2015-03-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01632904",
      "title": "Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study",
      "status": "COMPLETED",
      "last_update": "2017-11-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01644110",
      "title": "Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01693601",
      "title": "Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)",
      "status": "COMPLETED",
      "last_update": "2023-10-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01702064",
      "title": "Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients",
      "status": "COMPLETED",
      "last_update": "2021-01-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01712308",
      "title": "Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia",
      "status": "COMPLETED",
      "last_update": "2023-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01730248",
      "title": "A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2020-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732445",
      "title": "Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2017-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01751425",
      "title": "Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors",
      "status": "TERMINATED",
      "last_update": "2025-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01776723",
      "title": "A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib",
      "status": "COMPLETED",
      "last_update": "2022-09-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01787487",
      "title": "Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm",
      "status": "COMPLETED",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01787552",
      "title": "A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF",
      "status": "COMPLETED",
      "last_update": "2020-04-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01790295",
      "title": "Ruxolitinib Prior to Transplant in Patients With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2019-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01795677",
      "title": "JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2022-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914484",
      "title": "Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01969838",
      "title": "Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2023-05-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01981850",
      "title": "A Phase 2 Study of RO7490677 In Participants With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2022-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02038036",
      "title": "Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.",
      "status": "COMPLETED",
      "last_update": "2021-07-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02076191",
      "title": "Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML",
      "status": "COMPLETED",
      "last_update": "2019-02-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02087059",
      "title": "A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2016-07-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02091752",
      "title": "A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)",
      "status": "TERMINATED",
      "last_update": "2016-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02092324",
      "title": "Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02101268",
      "title": "Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF",
      "status": "COMPLETED",
      "last_update": "2023-05-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02158858",
      "title": "A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02226172",
      "title": "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib",
      "status": "TERMINATED",
      "last_update": "2019-01-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02251821",
      "title": "JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02253277",
      "title": "Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients",
      "status": "COMPLETED",
      "last_update": "2019-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257138",
      "title": "Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02267278",
      "title": "Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)",
      "status": "COMPLETED",
      "last_update": "2019-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02292446",
      "title": "Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.",
      "status": "COMPLETED",
      "last_update": "2019-07-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02370706",
      "title": "Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2022-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02386800",
      "title": "CINC424A2X01B Rollover Protocol",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02436135",
      "title": "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease",
      "status": "TERMINATED",
      "last_update": "2020-09-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02469974",
      "title": "Ruxolitinib in Combination With Autotransplant",
      "status": "WITHDRAWN",
      "last_update": "2016-08-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02493530",
      "title": "TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea",
      "status": "COMPLETED",
      "last_update": "2026-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02528877",
      "title": "Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",
      "status": "WITHDRAWN",
      "last_update": "2016-09-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02577926",
      "title": "The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02587598",
      "title": "Study of INCB053914 in Subjects With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2021-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02593760",
      "title": "A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)",
      "status": "COMPLETED",
      "last_update": "2018-05-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02598297",
      "title": "Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.",
      "status": "TERMINATED",
      "last_update": "2019-08-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02711137",
      "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-10-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02718300",
      "title": "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2024-05-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02742324",
      "title": "Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg",
      "status": "COMPLETED",
      "last_update": "2022-07-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02784496",
      "title": "Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2025-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02806375",
      "title": "PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2019-04-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02917096",
      "title": "Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2023-12-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02962388",
      "title": "The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line",
      "status": "TERMINATED",
      "last_update": "2021-06-29",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02966353",
      "title": "Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.",
      "status": "COMPLETED",
      "last_update": "2020-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02973711",
      "title": "A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML",
      "status": "WITHDRAWN",
      "last_update": "2021-02-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03069326",
      "title": "A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03123588",
      "title": "Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)",
      "status": "TERMINATED",
      "last_update": "2021-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03144687",
      "title": "A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2022-06-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03165734",
      "title": "A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03194542",
      "title": "A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence",
      "status": "COMPLETED",
      "last_update": "2023-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03222609",
      "title": "A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03287245",
      "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera",
      "status": "TERMINATED",
      "last_update": "2021-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03333187",
      "title": "Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03373877",
      "title": "Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2022-11-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03386214",
      "title": "Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2022-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03427866",
      "title": "Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03558607",
      "title": "The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm",
      "status": "UNKNOWN",
      "last_update": "2020-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610971",
      "title": "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03654768",
      "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03669965",
      "title": "KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2020-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03722407",
      "title": "Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03755518",
      "title": "A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib",
      "status": "TERMINATED",
      "last_update": "2024-12-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878199",
      "title": "Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms",
      "status": "TERMINATED",
      "last_update": "2026-04-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03935555",
      "title": "Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib",
      "status": "TERMINATED",
      "last_update": "2022-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03952039",
      "title": "An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib",
      "status": "COMPLETED",
      "last_update": "2025-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04016116",
      "title": "Dual PD-1 and JAK2 Inhibition in Hematological Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2020-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04041050",
      "title": "A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04097821",
      "title": "Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients",
      "status": "TERMINATED",
      "last_update": "2025-08-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04217993",
      "title": "Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2023-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04218071",
      "title": "Actuate 1901: 9-ING-41 in Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2024-02-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04279847",
      "title": "Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04281498",
      "title": "Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04328844",
      "title": "A Study to Assess a PI3K\u03b4 Inhibitor (IOA-244) in Patients With Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04354727",
      "title": "A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy",
      "status": "WITHDRAWN",
      "last_update": "2022-07-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04384692",
      "title": "Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04454658",
      "title": "Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04455841",
      "title": "INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04468984",
      "title": "Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04472598",
      "title": "Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-03-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04480086",
      "title": "Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2023-08-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04485260",
      "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib",
      "status": "UNKNOWN",
      "last_update": "2022-05-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04509700",
      "title": "Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04543279",
      "title": "Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia",
      "status": "TERMINATED",
      "last_update": "2023-12-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04551053",
      "title": "To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04551066",
      "title": "To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)",
      "status": "TERMINATED",
      "last_update": "2025-10-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04562389",
      "title": "Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04562870",
      "title": "A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04603495",
      "title": "Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04629508",
      "title": "To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)",
      "status": "COMPLETED",
      "last_update": "2025-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04640025",
      "title": "A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib",
      "status": "TERMINATED",
      "last_update": "2026-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04676529",
      "title": "Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis",
      "status": "COMPLETED",
      "last_update": "2026-08-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04817007",
      "title": "A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04851535",
      "title": "Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.",
      "status": "COMPLETED",
      "last_update": "2023-11-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04884191",
      "title": "Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib",
      "status": "COMPLETED",
      "last_update": "2022-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05088356",
      "title": "Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05371964",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05447260",
      "title": "A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis",
      "status": "UNKNOWN",
      "last_update": "2022-07-07",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05569538",
      "title": "Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis",
      "status": "UNKNOWN",
      "last_update": "2023-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05936359",
      "title": "A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06079879",
      "title": "A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06388759",
      "title": "TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients",
      "status": "TERMINATED",
      "last_update": "2025-08-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06397313",
      "title": "RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06619522",
      "title": "A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-na\u00efve Patients With Myelofibrosis",
      "status": "WITHDRAWN",
      "last_update": "2025-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06664970",
      "title": "A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2024-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07340138",
      "title": "Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07498205",
      "title": "Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07521046",
      "title": "Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07722611",
      "title": "A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07734077",
      "title": "Revumenib in Patients With Myelofibrosis",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SIREMADLIN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04097821",
      "title": "Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients",
      "status": "TERMINATED",
      "last_update": "2025-08-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VORASIDENIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04603001",
      "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "XL-019": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00522574",
      "title": "A Safety Study of XL019 in Adults With Myelofibrosis",
      "status": "TERMINATED",
      "last_update": "2011-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00595829",
      "title": "A Phase 1 Study of XL019 in Adults With Polycythemia Vera",
      "status": "TERMINATED",
      "last_update": "2015-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}